APAC – the first targeted therapy for peripheral arterial occlusive disease.

There is a major unmet need for effective and safe therapies for advanced peripheral arterial occlusive disease (PAOD) due to the high cardiovascular mortality, morbidity, and amputation rates in these patients. Aplagon is developing the first vascular injury -targeting product (APAC) for the local treatment of advanced PAOD.

PAOD is caused by fatty deposits in lower limb arteries (atherosclerosis) that become inflamed (thromboinflammation), resulting in blood coagulation (atherothrombosis).

APAC uniquely targets these vessels, prevents further atherosclerosis and downregulates thromboinflammation, the main drivers of PAOD.

Aplagon has completed preclinical proof-of-concept and toxicology studies and received a regulatory approval to enter clinical studies. Aplagon has an experienced, international team, and is supported by a renowned scientific advisory board.

We are applying for EIC-funding to show the safety and efficacy of APAC in PAOD/CLI-patients, a major value inflection point.